Vitro, HemoGenix Amend Cell-based Assay Alliance | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Vitro Diagnostics today announced that it has amended an agreement with HemoGenix covering stem cell analysis tools.

The amended agreement expands upon the original agreement to include development of stem cell culture media and high-performance toxicity assays for new cell-based tools for drug discovery and development. The firms also intend to align their respective quality programs to assure consistency, said Golden, Colo.-based Vitro.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.